Search results
Dec 26, 2023 · Harpoon is a biotech company developing novel biologics for cancer and other diseases using a proprietary antibody-based platform called TriTAC. TriTAC unleashes the target cell-killing properties of a patient’s own immune system by engaging T cells.
Jan 8, 2024 · Merck and Harpoon Therapeutics announce a definitive agreement under which Merck will acquire Harpoon for $680 million. Harpoon has a portfolio of novel T-cell engagers, including HPN328, a DLL3 targeting candidate for small cell lung cancer and neuroendocrine tumors.
Mar 11, 2024 · Merck completes the acquisition of Harpoon, a biotechnology company developing novel T-cell engagers for cancer treatment. Harpoon's lead candidate, MK-6070, is a DLL3 targeting T-cell engager for small cell lung cancer and neuroendocrine tumors.
Mar 11, 2024 · MSD (Merck & Co., Inc., Rahway, N.J., USA) completes the acquisition of Harpoon Therapeutics, a biopharmaceutical company developing novel T-cell engagers for cancer. Harpoon's lead candidate, MK-6070, is a DLL3 targeting T-cell engager for small cell lung cancer and neuroendocrine tumors.
Mar 11, 2024 · Merck completes the acquisition of Harpoon, a biotech company developing T-cell engagers for cancer treatment. Harpoon's lead candidate, MK-6070, targets DLL3 in small cell lung cancer and neuroendocrine tumors.
People also ask
What is harpoon Therapeutics?
Will Merck buy Harpoon Therapeutics?
What happened to harpoon Therapeutics?
Is harpoon a publicly traded company?
Oct 21, 2023 · SOUTH SAN FRANCISCO, Calif., Oct. 21, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today...
Jun 27, 2023 · SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today...